Do you want to read an article? Please log in or register.
Treatment intensity level as a proxy for severity of chronic obstructive pulmonary disease: A risk stratification tool
COPD
RECOMMENDED
Related content
COMMENTED
COPD
Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine Reduces Exacerbation Rate and Risk in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
★ 3
Recommended and commented by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Chest
Sciurba FC, Christenson SA, Rheault T, Bengtsson T, Rickard K, Barjaktarevic IZ
doi: 10.1016/j.chest.2024.07.168
COPDLung Cancer
Construction and Validation of a Nomogram Prediction Model for Death Risk in Patients with Chronic Obstructive Pulmonary Disease Complicated by Hypercapnic Respiratory Failure in the Intensive Care Unit
Respir Med
Zhang Y, Chen H, Hu S, Chen C, Chen W
doi: 10.1016/j.rmed.2025.108188
COPD
A Comparison of GOLD and STAR Severity Stages in Individuals with Chronic Obstructive Pulmonary Disease Undergoing Pulmonary Rehabilitation
Chest
Ambrosino P, Vitacca M, Marcuccio G, Spanevello A, Ambrosino N, Maniscalco M
doi: 10.1016/j.chest.2024.10.013
COMMENTED
COPD
Exacerbation history and risk of myocardial infarction and pulmonary embolism in chronic obstructive pulmonary disease
★ 3
Recommended and commented by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Chest
Wallström O, Stridsman C, Lindberg A, Nyberg F, Vanfleteren LEGW
doi: 10.1016/j.chest.2024.07.150
RECOMMENDED
COPDFurther Publications
Global, regional, and national burden of chronic obstructive pulmonary disease and its attributable risk factors from 1990 to 2021: an analysis for the Global Burden of Disease Study 2021
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Respir Res
Wang Z, Lin J, Liang L, Huang F, Yao X, Peng K, Gao Y, Zheng J
doi: 10.1186/s12931-024-03051-2
RECOMMENDED
COPDInterstitial Lung Disease
Pulmonary Rehabilitation and Functional Independence: Impact on Survival in Patients with Fibrotic Interstitial Lung Disease or Chronic Obstructive Pulmonary Disease
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med
Elmiger A, Marcin T, Bovet L, Brun P, Guler SA
doi: 10.1016/j.rmed.2024.107933
RECOMMENDED
COPD
Prognostic risk prediction model for patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD): a systematic review and meta-analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Res
Xu Z, Li F, Xin Y, Wang Y, Wang Y
doi: 10.1186/s12931-024-03033-4
RECOMMENDED
COPD
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Singh D, Brightling CE, Rabe KF, Han MK, Christenson SA, Drummond MB, Papi A, Pavord ID, Molfino NA, Almqvist G, Kotalik A, Hellqvist Å, Gołąbek M, Sindhwani NS, Ponnarambil SS, COURSE study investigators
doi: 10.1016/S2213-2600(24)00324-2
AsthmaCOPD
Burden of Respiratory Syncytial Virus Disease in Adults with Asthma and Chronic Obstructive Pulmonary Disease: A Systematic Literature Review
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended and commented by
Dr Marcus Hesse, Faculty Member
Curr Allergy Asthma Rep
Penders Y, Brusselle G, Falsey AR, Rohde G, Betancur E, Guardado ME, Agudelo JLR, Saeedi P, Harrington L, Michaud JP
doi: 10.1007/s11882-025-01194-w